Etoposide-induced angina in a patient with small cell lung carcinoma: a case report

BACKGROUND: The combination of cisplatin and etoposide is a standard therapy for small cell lung cancer; however, ischemic heart disease is a known complication. We report a rare case of effort angina pectoris that worsened during initial treatment of small cell lung cancer with etoposide. CASE PRESENTATION: A 73-year-old Asian male was admitted to our hospital with effort angina. Coronary angiography revealed severe stenosis with significant calcification of the proximal right coronary artery. Computed tomography revealed a 21-mm-sized nodule in the right upper lobe and hilar lymphadenopathy suggestive of lung cancer. The patient underwent thoracoscopic wedge resection before coronary revascularization, and intraoperative findings indicated a small cell carcinoma with hilar lymph node metastases. Early postoperative definitive treatment consisting of chemotherapy with cisplatin plus etoposide and accelerated hyperfractionated radiation was planned. During the first chemotherapy session, on postoperative day 7, the patient complained of chest pain, and an electrocardiogram showed slight ST depression in leads V5 and V6 while receiving etoposide; nitroglycerin improved his symptoms. Although treatment was resumed with the administration of nicorandil the next day, the same symptoms were observed during the infusion of etoposide. Accordingly, chemoradiation therapy was suspended and revascularization of the right coronary artery was performed. Etoposide and cisplatin were readministered 3 days after revascularization, without any chest symptoms. CONCLUSION: Chemotherapy for malignant tumors carries the risk of progression to coronary artery disease. To prevent serious ischemic events, sufficient discussions between oncologists and cardiologists and careful observation of chest symptoms are needed.

Authors

Institutions

Publication Details

Journal
Journal of Medical Case Reports
Published
2026-11-13
DOI
https://doi.org/10.1186/s13256-025-05600-9
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Etoposide-induced angina in a patient with small cell lung carcinoma: a case report

Teisuke Anzai, Shogo Imagawa, Nozomu Iwashiro, Shinya Otsuka et al.
2 links
Journal of Medical Case Reports
Chemotherapy-induced cardiotoxicity and mitigation
article

Etoposide-induced angina in a patient with small cell lung carcinoma: a case report

Teisuke Anzai, Shogo Imagawa, Nozomu Iwashiro, Shinya Otsuka, Yasuyuki Chiba, Kei Hiraoka, Kazuya Yonezawa, Kyo Shimazu, Kenta Otsuka
article en

Abstract

BACKGROUND: The combination of cisplatin and etoposide is a standard therapy for small cell lung cancer; however, ischemic heart disease is a known complication. We report a rare case of effort angina pectoris that worsened during initial treatment of small cell lung cancer with etoposide. CASE PRESENTATION: A 73-year-old Asian male was admitted to our hospital with effort angina. Coronary angiography revealed severe stenosis with significant calcification of the proximal right coronary artery. Computed tomography revealed a 21-mm-sized nodule in the right upper lobe and hilar lymphadenopathy suggestive of lung cancer. The patient underwent thoracoscopic wedge resection before coronary revascularization, and intraoperative findings indicated a small cell carcinoma with hilar lymph node metastases. Early postoperative definitive treatment consisting of chemotherapy with cisplatin plus etoposide and accelerated hyperfractionated radiation was planned. During the first chemotherapy session, on postoperative day 7, the patient complained of chest pain, and an electrocardiogram showed slight ST depression in leads V5 and V6 while receiving etoposide; nitroglycerin improved his symptoms. Although treatment was resumed with the administration of nicorandil the next day, the same symptoms were observed during the infusion of etoposide. Accordingly, chemoradiation therapy was suspended and revascularization of the right coronary artery was performed. Etoposide and cisplatin were readministered 3 days after revascularization, without any chest symptoms. CONCLUSION: Chemotherapy for malignant tumors carries the risk of progression to coronary artery disease. To prevent serious ischemic events, sufficient discussions between oncologists and cardiologists and careful observation of chest symptoms are needed.

Journal of Medical Case ReportsVol. 20(1)
National Hospital Organization (JP), Hakodate National Hospital (JP)
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon